Compare SNDA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDA | CTMX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.2M | 596.2M |
| IPO Year | 1997 | 2015 |
| Metric | SNDA | CTMX |
|---|---|---|
| Price | $32.69 | $4.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $6.50 |
| AVG Volume (30 Days) | 51.6K | ★ 2.9M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $327,007,000.00 | $113,631,000.00 |
| Revenue This Year | $27.08 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | ★ N/A | $16.70 |
| Revenue Growth | ★ 29.15 | N/A |
| 52 Week Low | $19.34 | $0.40 |
| 52 Week High | $33.50 | $4.62 |
| Indicator | SNDA | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 63.70 | 51.75 |
| Support Level | $30.78 | $3.86 |
| Resistance Level | $33.20 | $4.37 |
| Average True Range (ATR) | 0.99 | 0.27 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 85.59 | 48.95 |
Sonida Senior Living Inc is an owner operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.